Efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) for schizophrenia in southwestern China.

ABSTRACT:

Background

This clinical pilot initiative, led by the Sichuan Provincial Government in western China, aims to develop an innovative model for "integrated hospital-community management and treatment of severe mental disorders" to enhance the management of patients with such conditions. This single-arm, open-label, prospective, multicenter, interventional study was designed to evaluate the efficacy and safety of paliperidone palmitate 1-month formulation (PP1M) in patients with schizophrenia.

Methods

The study enrolled patients with schizophrenia aged 18-55 from all 21 prefectural-level municipalities in Sichuan Province, southwestern China, who received PP1M at doses of 75, 100, or 150 mg. Efficacy and social functioning were assessed using the PANSS and SDSS scales at baseli

SUBMITTER: Gou L 

PROVIDER: S-EPMC11980341 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature